title: [Auto-analysis of immunohistochemical findings for breast cancer using specified software and virtual microscopy].
abstract: Currently, the therapeutic strategy for a breast cancer patient is designed according to their histopathological, immunohistochemical and molecular findings. These findings are obtained through the collected efforts of many individual pathologists or medical technologists (MTs) and are, thus, limited by intra-observer error and potentially subjective decision making. Twenty five breast cancer specimens collected between November 2009 and February 2010 were examined for immunohistochemical expressions of estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki-67, Topoisomerase II alpha (Topo IIalpha). Fifty one cancer specimens collected November 2009 and June 2010 were examined for human epidermal growth factor 2 (HER2). Immunohistochemical staining was performed using auto-stainers (Ventana) and the results were stored digitally after examination by virtual microscopy (Hamamatsu Photonics). Data analysis was performed with the Genie/Aperio software package on a desk-top computer. For all the antibodies used expect for HER2, concordant results were obtained in 100% of 24 ER positive cases. Ki-67 index (r=0.96) and Topo IIalpha index (r=0.95) also showed a significant correlation (p<0.001). For HER2, all four specimens with Hercep-score 2 by ocular observation but auto-analysis score 1 revealed no HER2 gene amplification. Well-organized auto-analysis is more likely to result in an objective observation and to provide a means by which to standardize the methods for immunohistochemical detection of breast cancer.
authors.affiliation: Institute for Clinical Research, National Hospital Organization, Kure Medical Center and Cancer Center, Kure 737-0023, Japan.
authors.forename: Miho
authors.initials: M
authors.lastname: Tanaka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kuraoka
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakane
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kodama
authors.forename: Toshinao
authors.initials: T
authors.lastname: Nishimura
authors.forename: Masazumi
authors.initials: M
authors.lastname: Tanaka
authors.forename: Junji
authors.initials: J
authors.lastname: Tatsushima
authors.forename: Akihisa
authors.initials: A
authors.lastname: Saitou
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Taniyama
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis*; D044584:Carcinoma, Ductal / Q000175:diagnosis*; D004250:DNA Topoisomerases, Type II / Q000032:analysis; D004268:DNA-Binding Proteins / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008853:Microscopy / Q000379:methods*; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012984:Software; D014584:User-Computer Interface
chemical_list: D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human